Condition: Glioblastoma · GBM · Sponsor: Alpheus Medical, Inc.
The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to see if it is useful in treating glioblastoma following standard of care therapy surgery and chemoradiation. This study is evaluating an experimental treatment for glioblastoma that uses an investigational drug (5-ALA) combined with a non-invasive ultrasound device (LIDU) to target tumor cells. Patients meeting the entry requirements to be in the study, will be equally randomly assigned to receive the study device plus the active study drug plus active ultrasound, or to a "sham" procedure where the ultrasound is not being activated and the study drug is a placebo (looks the same but does not contain active drug). Neither the patient or the investigator will know who is in the active group or not. Both groups will continue to receive the standard therapy of oral Temozolomide.
This description comes directly from the study's public registry record.
Ann-Marie VP, Clinical Operations · 4842521960 · AMHulstine@alpheusmedical.com
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Albany Medical Center | Albany, New York, United States | Recruiting |
| Dent Neurologic Institute | Buffalo, New York, United States | Recruiting |
| Northwell Health | Long Island City, New York, United States | Recruiting |
| New York Langone | New York, New York, United States | Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| University of Rochester | Rochester, New York, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Recruiting |
| Penn State Milton S. Hershey Medical Center | Hershey, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07225621